• Japanese
  • Korean
  • Chinese
Cover Image

Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022

Abstract

Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, "Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Multaq global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US and EU5 (six major markets)
  • Analysis and review of Multaq including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Multaq including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2009-2022 for Multaq

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Multaq, dronedarone, class III antiarrhythmic, paroxysmal atrial fibrillation, persistent atrial fibrillation, cardiovascular hospitalizations

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Introduction 4

  • 2.1 Atrial Fibrillation Market 4
  • 2.2 Epidemiology 4
  • 2.3 Etiology and Risk Factors 5
    • 2.3.1 Symptoms associated with AF 6
  • 2.4 GlobalData Analysis and Forecasts Report Guidance 7

3 Atrial Fibrillation: Market Characterization 8

  • 3.1 Atrial Fibrillation Market 8
  • 3.2 Atrial Fibrillation Market Forecasts and CAGR 9
  • 3.3 Drivers of Atrial Fibrillation Market 9
    • 3.3.1 High Unmet need 9
    • 3.3.2 Strong Pipeline 10
    • 3.3.3 Increase in prevalence and ageing populations 10
    • 3.3.4 Organisation of Awareness Campaigns 11
  • 3.4 Barriers in Atrial Fibrillation Market 12
    • 3.4.1 Limitations in established therapies 12
    • 3.4.2 High cost of emerging therapies 12

4 Classification in Atrial Fibrillation: Introduction 13

  • 4.1 AF Classification 13
    • 4.1.1 Pathophysiology of AF 14
    • 4.1.2 Diagnosis in Atrial Fibrillation 15
    • 4.1.3 Impact of Atrial Fibrillation 16

5 Treatment Options and Management in Atrial Fibrillation 17

  • 5.1 Rate control and Rhythm control 17
  • 5.2 Rate Control Versus Rhythm Control 19

6 Multaq 20

  • 6.1 Introduction 20
  • 6.2 Mechanism of Action 20
  • 6.3 Clinical Studies 20
  • 6.4 Approval Status of Multaq 21
  • 6.5 Factors Affecting Sales of Eliquis 21
    • 6.5.1 Unique Drug with significant opportunity 21
    • 6.5.2 Low adverse effect profile 21
    • 6.5.3 Causative factor for Liver injury in some patients 22
    • 6.5.4 Second black box Warning for Multaq 22
  • 6.6 Drug Evaluation 22
    • 6.6.1 Drug Risk Benefit Score 22
    • 6.6.2 Intensity of Competition 24
  • 6.7 Sales Forecasts 24
    • 6.7.1 Target Patient Pool of Multaq 24
    • 6.7.2 Dosing 25
    • 6.7.3 Market Penetration 25
    • 6.7.4 Annual Cost of Therapy 25
    • 6.7.5 Global Sales Projections of Multaq 26

7 Appendix 34

  • 7.1 Market Definitions 34
  • 7.2 Abbreviations 34
  • 7.3 Research Methodology 34
    • 7.3.1 Coverage 34
    • 7.3.2 Secondary Research 35
    • 7.3.3 Forecasting 35
    • 7.3.4 Number of Patients Approved to Take the Drug 35
    • 7.3.5 Net Penetration of Drug 36
    • 7.3.6 Net Annual Dosing 36
    • 7.3.7 Annual Cost of Therapy 36
  • 7.4 Drug Sales Estimates Model 36
  • 7.5 Contact Us 36
  • 7.6 Disclaimer 37
  • 7.7 Sources 37

List of Tables

1.1 List of Tables

  • Table 1: Epidemiology of Atrial Fibrillation (2011) 5
  • Table 2: Increase in the Risk of AF in The Presence of Risk Factors 5
  • Table 3: Stratification of All Risk Factors For Atrial Fibrillation 6
  • Table 4: Atrial Fibrillation Classification 14
  • Table 5: Treatment Guidelines For the Management of Atrial Fibrillation 17
  • Table 6: Multaq, Approval Status, 2011 21
  • Table 7: Drug Risk Benefit Score of Multaq 22
  • Table 8: Multaq, Atrial Fibrilation, Global, Annual Cost of Therapy, 2011 25
  • Table 9: Multaq, Atrial Fibrillation, Global, Sales Forecasts ($m), 2009-2022 26
  • Table 10: Multaq, Atrial Fibrillation, The US, Sales Forecasts ($m), 2009-2022 27
  • Table 11: Multaq, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010-2022 28
  • Table 12: Multaq, Atrial Fibrillation, France, Sales Forecasts ($m), 2010-2022 29
  • Table 13: Multaq, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010-2022 30
  • Table 14: Multaq, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010-2022 31
  • Table 15: Multaq, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010-2022 32

List of Figures

1.2 List of Figures

  • Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011-2022 9
  • Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation 10
  • Figure 3: Increase of Prevalance Population in Atrial Fibrillation 11
  • Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation 13
  • Figure 5: Broad classification of Patterns in Atrial Fibrillation 14
  • Figure 6: Disease States Associated with Atrial Fibrillation, By (%) 15
  • Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF) 18
  • Figure 8: Management of Newly Discovered Atrial Fibrillation (AF) 18
  • Figure 9: Drug Model Diagram of Multaq 24
  • Figure 10: Multaq, Atrial Fibrillation, Global, Sales Forecasts ($m), 2009-2022 26
  • Figure 11: Multaq, Atrial Fibrillation, The US, Sales Forecasts ($m), 2009-2022 27
  • Figure 12: Multaq, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010-2022 28
  • Figure 13: Multaq, Atrial Fibrillation, France, Sales Forecasts ($m), 2010-2022 29
  • Figure 14: Multaq, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010-2022 30
  • Figure 15: Multaq, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010-2022 31
  • Figure 16: Multaq, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010-2022 32
  • Figure 17: Distribution of Multaq Sales in % by Countries, 2018 33
  • Figure 18: Patients Approved for the Drug 35
Show More
Pricing